Recall of 10 batches of Osteomel Once Weekly 70 mg tablets, PA0126/148/002

Notice type: Recall

Date: 29/02/2024

We wish to advise you that ten batches of Osteomel Once Weekly 70 mg tablets, PA0126/148/002, are being recalled with immediate effect.

This recall is going to pharmacy level.

The reason for the recall is due to out of specification results for the parameter disintegration identified in a number of batches.


Pharmacists can download a copy of the pharmacy recall letter here

As the recall is to pharmacy level, patients are not required to take any actions. 
 


Product name or type:
Osteomel Once Weekly 70 mg tablets


Authorisation Number:
PA0126/148/002


Serial Or Batch Number And Expiry Date:

Batch number

Expiry date

11AEYE

03/2024

11VARD

01/2025

128SHH

07/2025

12EKGC

09/2025

12LPHD

12/2025

12UEVR

03/2026

133WFA

06/2026

13EM1C

11/2026

13KRCD

12/2026

13S89A

03/2027

 



Authorisation Holder:
Clonmel Healthcare Ltd. 


Prescription Required:
Yes


Recall Classification:
Pharmacy level recall


Target Audience:
Pharmacists and Wholesalers 


Actions To Be Taken:
Information for pharmacists:

Pharmacists are requested to carry out the following actions:

 
1. Immediately quarantine any units of the above-listed batches which you have in your possession or are returned to you.  For hospital pharmacists, this includes stock at ward or clinic level. Please make relevant staff at your facility aware of the contents of this recall notification. 
2. Complete the customer return form provided with the recall letter and return it via email to Clonmel Healthcare Ltd.  
3. Return impacted stock to Clonmel Healthcare Ltd. by Friday 16th March 2024. 
4. If you have supplied any other pharmacy, clinic, or healthcare facility with units from the above-listed batches, immediately forward a copy of the recall letter to them, requesting that they quarantine and return any units of the impacted batches to you.

 

Un-affected stock is available to order at this time from wholesalers.

Information for patients:

No action is required at patient level; however, if you have any concerns, please contact your pharmacist. 




« Back